康缘药业：围绕老年人健康需求，公司在老龄化相关疾病治疗领域拥有核心产品

Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in accordance with supplementary material requirements and will disclose key information as per legal obligations [1] Group 1: Company Developments - The company is actively contributing to the macroeconomic strategy addressing population aging, focusing on traditional Chinese medicine [1] - Kangyuan has core products targeting health needs of the elderly, including treatments for cardiovascular diseases and bone injuries, such as Ginkgo Biloba Diterpene Injection and Tian Shu Capsules [1] - The company is also developing treatments for Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with related products entering clinical stages [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported revenue of 2.343 billion yuan, a year-on-year decrease of 24.59% (adjusted) [1] - The net profit attributable to the parent company was 200 million yuan, reflecting a year-on-year decline of 35.63% [1]